Genetically Engineered Mesenchymal Stem Cell Therapy Against Murine Experimental Autoimmune Encephalomyelitis

Area of Science:

• Immunology
• Neuroscience
• Regenerative Medicine

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
• Mesenchymal stem cells (MSCs) show therapeutic potential but require enhancement for autoimmune conditions.
• Interleukin-23 receptor (IL-23R) signaling plays a role in T cell-mediated inflammation relevant to MS.

Purpose of the Study:

• To engineer mesenchymal stem cells (MSCs) with recombinant interleukin-23 receptor (RIL-23R) for enhanced therapeutic efficacy.
• To evaluate the therapeutic potential of RIL-23R-engineered MSCs in a mouse model of experimental autoimmune encephalomyelitis (EAE), a model for MS.
• To assess the impact of RIL-23R modification on MSC properties, including migration, immune suppression, and therapeutic outcomes in vivo.

Main Methods:

• Recombinant IL-23 receptor (RIL-23R) construct was designed for MSC transfection.
• Bioactivity of RIL-23R constructs was assessed via co-culture with CD4+ T cells.
• The EAE mouse model was induced, followed by transplantation of RIL-23R-engineered MSCs; clinical scores and demyelination (Luxol fast blue staining) were evaluated.

Main Results:

• Transfection with RIL-23R mRNA significantly improved MSC properties and homing to inflamed regions in EAE mice.
• RIL-23R-engineered MSCs exhibited enhanced suppressive function on T lymphocyte proliferation.
• In vivo therapy with RIL-23R MSCs demonstrated improved myelination and reduced inflammatory cell infiltration in the white matter compared to unmodified MSCs.

Conclusions:

• Engineering MSCs with RIL-23R enhances their therapeutic potential for autoimmune diseases like MS.
• Targeted transplantation of modified MSCs offers a promising strategy to improve cellular therapy effectiveness.
• This approach holds potential for treating multiple sclerosis and other autoimmune disorders.